Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma

Fig. 1

Cotreatment with a HDAC inhibitor and bromodomain inhibitor synergistically inhibits cell viability in GBM cells. a-c Cotreatment with a HDAC inhibitor (panobinostat or vorinostat) and bromodomain inhibitor JQ1 at various indicated dosages synergistically inhibits cell viability in U87, U251 and serum-free cultured U87 cells. The combination indices are shown on the left. d Time course tracking of cell viability after the cotreatment with panobinostat and JQ1 at various indicated dosages in U87, U251 and serum-free cultured U87 cells

Back to article page